Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Exelixis, Inc.; Genomic Health, Inc.; Karyopharm Therapeutics; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme; and Seagen Inc.

3rd Annual Precision Medicine Symposium: An Illustrated Tumor Board

Release Date: November 30, 2021
Expiration Date: November 30, 2022

Activity Overview

This online educational activity is designed to provide expert commentary regarding the role of precision medicine in major solid and liquid tumors. The latest updates in next-generation sequencing, liquid biopsy, and cytogenetic testing will be discussed. This activity will emphasize the role of advanced genetic panel testing and the use of targeted therapies as well as best practices for leveraging relevant actionable targets that drive clinical decision-making, with a focus on data that is most relevant for patient care. This activity is presented in a multimedia format that includes a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward oncologists and pathologists as well as nurses and fellows involved in the treatment and management of patients with cancer. Physician assistants, pharmacists, researchers, and other health care professionals may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Evaluate clinical data regarding the use of biomarkers in qualifying patients for specific oncolytic therapies
Interpret tumor pathology reports to facilitate evidence-based treatment across malignancies
Summarize diagnostic and treatment-related data relevant to optimal multidisciplinary care
Evaluate the most relevant data regarding the current and evolving role of genomic assays in cancer management

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Faculty

Andre H. Goy, MD
Physician in Chief, Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology - Hackensack Meridian School of Medicine
Professor of Medicine – Georgetown University
Hackensack, NJ

Disclosures: Grant research support: Principal Investigator: Acerta Pharma, AstraZeneca, Celgene Corporation, Constellation Pharmaceuticals, Genentech/Hoffman-La Roche, Infinity Pharmaceuticals, Infinity Pharmaceuticals/Verastem Oncology, Janssen Pharmaceutica, Karyopharm Therapeutics, Kite Pharma, Pharmacyclics; Consultant: Acerta Pharma, Celgene Corporation, Gilead Sciences, Janssen Pharmaceutica, Kite Pharma, Xcenda; Shareholder: COTA; Other: Honoraria: AstraZeneca, Gilead Sciences, Celgene Corporation, Kite Pharma, Xcenda; Advisory: AstraZeneca, COTA, Elsevier Oncology PracticeUpdate, Gilead Sciences, Janssen Pharmaceutica, Kite Pharma

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
(Medical Oncology)
Professor of Pharmacology
Director, Center for Thoracic Cancers
Chief, Medical Oncology
Associate Director, Translational Research Yale Cancer Center and Smilow Cancer
Hospital
New Haven, CT

Disclosures: Grant research support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company; Consultant: AbbVie, ARMO Biosciences, AstraZeneca, Bayer HealthCare Pharmaceuticals, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, eFFECTOR Therapeutics, Eli Lilly and Company, EMD Serono, Foundation Medicine, Genentech/Hoffmann-La Roche, Genmab, Gilead Sciences, Halozyme Therapeutics, Heat Biologics, HiberCell, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Johnson & Johnson, Loxo Oncology, Merck & Co, Mirati Therapeutics, Nektar Therapeutics, Neon Therapeutics, NextCure, Novartis Pharmaceuticals Corporation, Ocean Biomedical, Oncternal Therapeutics, Pfizer, Refactor Health, Ribon Therapeutics, Sanofi, Seattle Genetics, Shire Pharmaceuticals, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Symphogen, Takeda Pharmaceutical Company, Tesaro, Tocagen, Ventana Medical Systems, WindMIL Therapeutics, Xencor; Other: Board Member (non-executive/ independent): Immunocore Holdings Ltd, Junshi Biosciences.

Claudine Isaacs, MD
Professor of Medicine and Oncology
Co-Director, Breast Cancer Program
Medical Director, Fisher Center for Hereditary Cancer and Clinical Genomics Research
Lombardi Comprehensive Cancer Center at Georgetown University
Washington, DC

Disclosures: Grant research support: Pfizer, Tesaro; Consultant: AstraZeneca, Eisai, Genentech, Novartis Pharmaceuticals Corporation, Pfizer, Puma Biotechnology, Sanofi, Seattle Genetics; Speakers’ bureau: Genentech

Benjamin P. Levy, MD
Associate Professor of OncologyJohns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital
Washington, DC

Disclosures: Consultant: AstraZeneca, Daiichi Sankyo, Genentech, Janssen Pharmaceuticals, Merck & Co, Pfizer, Takeda Pharmaceutical Company

John L. Marshall, MD
Professor of Medicine and Oncology
Lombardi Comprehensive Cancer Center, Georgetown University
Chief, Division of Hematology/Oncology, MedStar Georgetown University Hospital
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer
Washington, DC

Disclosures: Grant research support: Amgen, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Celgene Corporation, Indivumed, Merck & Co, Taiho Pharmaceutical; Consultant: Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Daiichi Sankyo, Indivumed, Ipsen Biopharmaceuticals, Merck & Co, Pfizer; Speakers’ bureau: Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Daiichi Sankyo, Merck & Co, Pfizer, Taiho Pharmaceutical

Eileen M. O’Reilly, MD
Associate Professor of Medicine
Weill Cornell Medicine
Winthrop Rockefeller Endowed Chair in Medical Oncology
Co-Director, Medical Initiatives
David M. Rubenstein Center for Pancreatic Cancer Research
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers, Gastrointestinal Oncology Service
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant research support: Arcus Biosciences, AstraZeneca, BioAtla, BioNTech, Celgene Corporation/Bristol Myers Squibb, Genentech/Hoffman-La Roche, Elicio Therapeutics, Parker Institute for Cancer Immunotherapy; Consultant: AstraZeneca, Bayer HealthCare Pharmaceuticals (spouse), BioNTech, BioSapien, Boehringer Ingelheim, Celgene Corporation/Bristol Myers Squibb (spouse), CytomX Therapeutics (Data Safety Monitoring Board [DSMB]), Eisai Co (spouse), Ipsen Biopharmaceuticals, Merck & Co, Genentech/Hoffmann-La Roche (spouse), Molecular Templates, NOXXON Pharma, Polaris Healthcare, Rafael Pharmaceuticals (DSMB), Sobi, Silenseed, Tyme Technologies, Seagen

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.